Page 1 of 139
NR 565 Final Exam – Advanced Pharmacology Fundamentals
EXAM QUESTIONS AND CORRECT VERIFIED SOLUTIONS LATEST
UPDATE THIS YEAR – JUST RELEASED
NR 565 Final Exam – Advanced Pharmacology Fundamentals
Unit 1: Foundations of Pharmacology & Prescribing
Question 1
A patient asks how a medication taken by mouth produces an effect in the body. The APRN
explains that the process by which a drug is absorbed, distributed, metabolized, and excreted
is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Answer: C
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
encompassing absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
is what the drug does to the body.
, Page 2 of 139
Question 2
A drug that binds to a receptor and produces a response that is less than that of a full agonist,
even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
Answer: A
Rationale: A partial agonist has lower efficacy than a full agonist. It binds to and activates a
receptor but cannot produce a maximal response, even when all receptors are occupied.
Question 3
An APRN is prescribing a medication that is known to be a CYP450 enzyme inducer. What
effect will this have on other medications metabolized by that enzyme pathway?
A) Increased serum levels of the other medications, potentially leading to toxicity
B) Decreased serum levels of the other medications, potentially leading to therapeutic failure
C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
, Page 3 of 139
Answer: B
Rationale: CYP450 inducers increase the metabolic activity of liver enzymes, leading to faster
breakdown of medications metabolized through that pathway. This results in decreased serum
concentrations, which can lead to loss of therapeutic effect. (Mnemonic: CRAPGPS –
Carbamazepine, Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas).
Question 4
The primary site for drug metabolism in the body is the:
A) Kidneys
B) Liver
C) Lungs
D) Spleen
Answer: B
Rationale: The liver is the primary site for drug metabolism, containing the cytochrome P450
enzyme system essential for drug biotransformation. The kidneys are the main organs for drug
excretion, not metabolism.
Question 5
What does the term "bioavailability" refer to in pharmacokinetics?
, Page 4 of 139
A) The amount of drug excreted in the urine
B) The percentage of an administered dose of unchanged drug that reaches the systemic
circulation
C) The half-life of the drug in the body
D) The volume of fluid into which the drug distributes
Answer: B
Rationale: Bioavailability measures the extent and rate of drug entry into systemic circulation. It
reflects the fraction of an administered dose that reaches systemic circulation unchanged.
Question 6
The therapeutic index of a drug is a measure of its:
A) Efficacy
B) Potency
C) Safety
D) Bioavailability
Answer: C
Rationale: The therapeutic index is the ratio between the toxic dose (LD50) and the effective
dose (ED50), indicating the drug's safety margin. A higher therapeutic index indicates a wider
margin of safety.
NR 565 Final Exam – Advanced Pharmacology Fundamentals
EXAM QUESTIONS AND CORRECT VERIFIED SOLUTIONS LATEST
UPDATE THIS YEAR – JUST RELEASED
NR 565 Final Exam – Advanced Pharmacology Fundamentals
Unit 1: Foundations of Pharmacology & Prescribing
Question 1
A patient asks how a medication taken by mouth produces an effect in the body. The APRN
explains that the process by which a drug is absorbed, distributed, metabolized, and excreted
is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Answer: C
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
encompassing absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
is what the drug does to the body.
, Page 2 of 139
Question 2
A drug that binds to a receptor and produces a response that is less than that of a full agonist,
even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
Answer: A
Rationale: A partial agonist has lower efficacy than a full agonist. It binds to and activates a
receptor but cannot produce a maximal response, even when all receptors are occupied.
Question 3
An APRN is prescribing a medication that is known to be a CYP450 enzyme inducer. What
effect will this have on other medications metabolized by that enzyme pathway?
A) Increased serum levels of the other medications, potentially leading to toxicity
B) Decreased serum levels of the other medications, potentially leading to therapeutic failure
C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
, Page 3 of 139
Answer: B
Rationale: CYP450 inducers increase the metabolic activity of liver enzymes, leading to faster
breakdown of medications metabolized through that pathway. This results in decreased serum
concentrations, which can lead to loss of therapeutic effect. (Mnemonic: CRAPGPS –
Carbamazepine, Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas).
Question 4
The primary site for drug metabolism in the body is the:
A) Kidneys
B) Liver
C) Lungs
D) Spleen
Answer: B
Rationale: The liver is the primary site for drug metabolism, containing the cytochrome P450
enzyme system essential for drug biotransformation. The kidneys are the main organs for drug
excretion, not metabolism.
Question 5
What does the term "bioavailability" refer to in pharmacokinetics?
, Page 4 of 139
A) The amount of drug excreted in the urine
B) The percentage of an administered dose of unchanged drug that reaches the systemic
circulation
C) The half-life of the drug in the body
D) The volume of fluid into which the drug distributes
Answer: B
Rationale: Bioavailability measures the extent and rate of drug entry into systemic circulation. It
reflects the fraction of an administered dose that reaches systemic circulation unchanged.
Question 6
The therapeutic index of a drug is a measure of its:
A) Efficacy
B) Potency
C) Safety
D) Bioavailability
Answer: C
Rationale: The therapeutic index is the ratio between the toxic dose (LD50) and the effective
dose (ED50), indicating the drug's safety margin. A higher therapeutic index indicates a wider
margin of safety.
